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ABSTRACT 
OBJECTIVES. The Movember Foundation launched the Global Action Plan Prostate Cancer 
Active Surveillance (GAP3) initiative to create a global consensus on the selection and 
monitoring of men with low-risk prostate cancer (PCa) on active surveillance (AS). The aim of 
this study is to present data on inclusion and follow-up for AS in this unique global AS database.  
SUBJECTS/PATIENTS (OR MATERIALS) AND METHODS. Between 2014 and 2016, the 
database was created by combining patient data from 25 established AS cohorts worldwide 
(USA, Canada, Australasia, UK, Europe) (n=15,101). 
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS. Descriptive statistics were 
used to report clinical/demographic characteristics at time of PCa diagnosis, clinical follow-up, 
discontinuation of AS and subsequent treatment. Cumulative incidence curves were used to 
report discontinuation rates over time. 
RESULTS AND LIMITATION. At diagnosis, median age was 65 yr (IQR 60-70) and median 
PSA was 5.4 ng/ml (IQR 4.0-7.3). Most men had a clinical stage T1 (71.8%), a biopsy Gleason 
score of 6 (88.8%) and one tumor-positive biopsy core (60.3%). Men on AS had a median 
follow-up time of 2.2 years (IQR 1.0-5.0 years). After 5, 10 and 15 years of follow-up, 
respectively, 58%, 39% and 23% of men were still on AS. The current version of GAP3 has 
limited data from MRI, quality of life and genomic testing. 
CONCLUSIONS. GAP3 is the largest worldwide data effort integrating patient data from men 
with PCa on AS. The results will allow individual patients and clinicians to have greater 
confidence in the personalized decision to either delay or proceed with active treatment. Longer 
follow-up and the evaluation of imaging (MRI), new genomic markers and patient-related 
outcomes will result in even more valuable data and eventually in better patient outcomes. 
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INTRODUCTION 
Prostate cancer (PCa) is the second most common cancer in men, with nearly a million new 
cases diagnosed worldwide[1]. The numbers of men living with a diagnosis of PCa will likely 
continue to increase, as the population in many countries continues to age, and cancer is detected 
earlier, owing to the more widespread use of serum prostate specific antigen (PSA) testing[2, 3]. 
As a result, active surveillance (AS) was introduced as a management strategy for men with low-
risk PCa, with the intention to start curative treatment at the time of progression and to avoid 
overtreatment and its associated morbidities. In recent years, AS has evolved from an 
experimental protocol to a broadly accepted management strategy for men diagnosed with low-
risk PCa[4]. Contemporary data suggest that use of AS has increased globally[5-7].   
Nevertheless, identification of those patients whose disease is at low risk for progression 
is a critical and much debated issue when deciding which men will benefit from AS for their 
PCa[8]. Numerous agencies have endorsed clinical practice guidelines for the management of 
low-risk PCa, which include criteria for enrolment of patients in AS programmes and their 
subsequent management[3]. However, no consensus is available today. Variability in enrolment 
criteria and follow-up has been demonstrated in international and national series of AS[9]. 
Moreover, robust data from men with clinically insignificant PCa who are undergoing AS, 
especially from studies with long follow-up durations, is still limited. Hence, many important 
questions on AS remain unanswered: Which newly-diagnosed men should be considered suitable 
viable candidates for AS[10]? What constitutes an appropriate follow-up regimen for AS[10]? 
There is a need for a worldwide consensus regarding the optimal criteria and protocols for AS 
and more comparative data on patient selection and testing protocols[11]. 
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In August 2014, the Movember Foundation launched the Global Action Plan Prostate Cancer 
Active Surveillance initiative (GAP3). Milestones of the project include a global AS database for 
clinical, marker-related and imaging data. Its primary goal is to create a global consensus on the 
selection and monitoring of men with low risk PCa. Ultimately, worldwide uniform guidelines 
will be developed. The aim of the current study is to present data of this unique global dataset on 
inclusion and follow-up for AS in low-risk PCa. 
 
SUBJECTS/PATIENTS (OR MATERIALS) AND METHODS 
Study population 
Between 2014 and 2016, a global database was created by combining patient data from 
established AS cohorts worldwide. To assemble existing cohorts into a large consortium of 
cohorts, a new collaborative framework was needed. The GAP3 partners therefore developed 
documentation required for sharing and use of clinical data within the global database. The 
database has been developed at the site of Philips Electronics Nederland B.V. (“Philips”), 
Eindhoven, the Netherlands and is currently hosted by the Erasmus Medical Centre, Rotterdam, 
the Netherlands [12]. The GAP3 initiative is initiated and coordinated by the Erasmus Medical 
Centre, Rotterdam, the Netherlands. The Movember Foundation is the sole funder of the project.  
Funding has now been secured to provide sustainability of the GAP3 database until February 
2019. 
Requirements for participation in GAP3 included, amongst others, ethical approval for 
sharing digital patient data in a centralized global database, and an active registry of AS patients 
over the last two years or more, including at least ~50 patients annually. To date, 25 centers from 
the USA, Canada, Australasia, the UK and Europe fulfilled the requirements for participation 
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and joined the initiative (Table S1). References to the individual AS cohorts can be found in 
Table S1. The global database currently comprises data on 15,101 patients (Table S1) (database 
version ‘gap3data_2.3’, released in June 2017).  A summary of the entry criteria for each 
individual AS cohort is included in Table S2.  
Although many variations in protocols currently exist, most agree that the most suitable 
patients for AS are those with age>18, pretreatment clinical stage T1-T2 PCa, serum PSA ≤10 
ng/ml, a biopsy Gleason score of ≤6 or (3+4) 7, and a maximum of two tumour-positive biopsy 
core samples. Some protocols included PSA density (most often using a cutoff of 0.2 ng/ml2), the 
maximum extent of cancer per core (most often using a cutoff of 50%) and life expectancy (>10 
years) and adequate biopsy sampling as inclusion criteria for AS. As a result the following 
baseline  host (e.g. age, BMI, race, ethnicity, marital status, educational level, family history of 
PCa, smoking history and comorbidities/ overall health status) and tumour characteristics (e.g. 
clinical stage, PSA, prostatic volume, biopsy Gleason score, PSA density, number of biopsy 
cores with PCa, and maximum extent cancer per core) were recorded.  
In addition to baseline information, follow-up information was key for the entire GAP3 
project – it will allow us to shed light on current practice and outcomes with the final goal of 
providing consensus guidelines. A summary of the monitoring strategy for each individual AS 
cohort is included in Table S3. Following initiation of AS, almost all protocols recommend serial 
measurement of serum PSA levels, digital rectal examination (DRE) and surveillance biopsy 
sampling in order to identify pathological progression. Many uncertainties remain surrounding 
the optimal timing of these surveillance strategies. Some protocols recommend PSA levels 
measurements every three months, while others state that serum PSA monitoring should be 
implemented at intervals no more often than every six months after the start of AS. Some 
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protocols recommend DRE every six months, whilst others do not include DRE in follow up, due 
to the use of MRI. Substantial variation exists in the recommended frequency at which rebiopsy 
procedures should be conducted. Further, several protocols consider MRI for routine use in AS, 
again with differences between the recommended frequency, although most protocols 
recommend a 12 month interval. PSA kinetics and Quality of Life data are less frequently 
recommended as methods to identify whether or not a patients’ cancer has progressed. We 
therefore collected follow-up information on e.g. PSA, PSA kinetics (PSA doubling time and 
PSA velocity), T-stage by DRE, biopsy characteristics and MRI findings (e.g. suspicious lesions 
found on MRI).  Finally, the database contains information on discontinuation of AS (e.g. the 
reasons for stopping AS), and potential following treatments (e.g. radical prostatectomy (RP)) 
and cause of death. 
 
Statistical analyses 
Descriptive statistics were used to assess the clinical and demographic characteristics at time of 
PCa diagnosis for all men included in the GAP3 cohort, their clinical follow-up, discontinuation 
of AS and potential following treatments. Cumulative incidence curves were used to report 
discontinuation rates over time[13]. R was used to perform all analyses [14]. 
 
RESULTS 
The GAP3 database currently comprises data on 15,101 patients from 25 centers across 15 
countries (database version ‘gap3data_2.3’, released in June 2017). At time of diagnosis, median 
age was 65 yr (IQR 60-70); median PSA was 5.4 ng/ml (IQR 4.0-7.3); median PSA density was 
0.12 ng/ml (IQR 0.09-0.17); and median prostate volume was 43.2 cc (IQR 33-59). Most men 
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had a clinical stage T1 (71.8%), a biopsy Gleason score of 6 (88.8%), one tumor-positive biopsy 
core (60.3%) and no comorbidity (25%) (Table 1; see table S4 for characteristics at time of PCa 
diagnosis for all men included in the GAP3 cohort for each participating center). Men on AS had 
a median follow-up time (i.e. the time until discontinuation or the time until the last known 
follow-up without discontinuation being reported) of 2.16 years (IQR 1.02-4.47 years). 
Maximum follow-up time was 21.3 years. The median number of years until their last follow-up 
while on AS was 1.99 yr (0.83-4.24). (Table 2).  
Until the end of current follow-up, 45 men (0.3%) developed metastases and 566 men 
(3.7%) died, of which 37 due to PCa (0.2%) (Table 2). The main clinical and demographic 
characteristics and clinical follow-up for all men that developed metastases during AS (n=45) 
and for all men that developed metastases and died of PCa (n=17) are summarized in table 3.Of 
all men that developed metastasis, median age was 66 yr (IQR 62-72); median PSA was 6.9 
ng/ml (IQR 4.8-8.7); median PSA density was 0.14 ng/ml (IQR 0.10-0.19); and median prostate 
volume was 44 cc (IQR 31-55) at time of diagnosis. Most men had a clinical stage T1 (44.4%), a 
biopsy Gleason score of 6 (68.3%), one tumor-positive biopsy core (42.4%); none of them had 
comorbidity. Median time to metastasis was 6.4 years. Of 45 men that developed metastases, 17 
died of PCa. Of those 17 men that died of PCa, median age was 66 yr (IQR 64-72); median PSA 
was 7.9 ng/ml (IQR 4.3-12.5); median PSA density was 0.14 ng/ml (IQR 0.11-0.19); and median 
prostate volume was 41 cc (IQR 29-50) at time of diagnosis. Most men had a clinical stage T2 
(41.2%), a biopsy Gleason score of 6 (66.7%), with one (41.7%), two (33.3%), and three or more 
tumor-positive biopsy cores (25.0%); none of them had comorbidity. Median time to death was 
8.8 years in these 17 patients Of all men that died of PCa until the end of current follow-up 
(n=37), a total of 32 men switched to curative treatment, of which 21 to androgen deprivation 
 
 
7 
 
therapy, four to external beam radiotherapy, two to external beam radiotherapy and 
brachytherapy, one to external beam radiotherapy and androgen deprivation, and four to radical 
prostatectomy.  
A total of 5,625 (37%) men discontinued AS for the following reasons: 46.2% for 
protocol-based progression, 3.3% switched to watchful waiting (WW), 9.1% discontinued due to 
patient or clinician choice, 7.0% died, and 25.1% discontinued for unknown reasons. For all men 
that discontinued AS, treatment was reported in 73% of the cases (n=4124). Treatment after 
discontinuation was radical prostatectomy in 51.6% of men, external beam radiotherapy in 
13.2% of men; brachytherapy in 9.3% of men and primary ADT/hormonal therapy in 8.4% of 
men (Table 2). Figure 1 shows cumulative incidence curves for reasons of discontinuing AS. The 
percentage of total area shaded for each color in the figure can be interpreted, at any time point, 
as the risk of discontinuing AS for that stated reason. 
 
Of the 15,101 patients, 1068 patients (7.1%) did not have available follow-up data yet. Among 
the remaining 14,033 patients, after 5, 10 and 15 years of follow-up, respectively, 58%, 39% and 
23% of men were still on AS; 23%, 30% and 36% discontinued due to protocol-based 
progression; 5%, 5% and 6% discontinued due to patient or clinician choice; 1%, 3% and 3% 
switched to watchful waiting (WW); 2%, 7% and 12% died (mostly of another cause), and 11%, 
16%, 20% discontinued for unknown reasons.  
 
DISCUSSION 
In recent years, AS has evolved from an experimental protocol to become a broadly accepted—
in fact, preferred—management strategy for men diagnosed with low-risk PCa [15].  
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Nevertheless, consensus on inclusion criteria, surveillance schedules and intervention thresholds 
for AS of men with low risk PCa is currently lacking. With this in mind, the Movember 
Foundation launched the GAP3 initiative.   
 Several findings deserve particular attention. GAP3 is the largest effort of its type to 
integrate patient data from men with prostate cancer on AS. With more than 15,000 patients, the 
Movember AS database is the largest centralized prostate cancer AS database to date, comprising 
the majority of the world’s AS patient data. Large volumes of AS data have been collected 
routinely for many years by the affiliated centers worldwide. Hence, the central data source 
enables comparisons of determinants for inclusion and follow-up in AS, and subsequent clinical 
outcomes (e.g. disease progression), between cohorts and countries and it allows us to determine 
variable patterns over time. Data capture is nearly complete (i.e. available for at least 90% of the 
centers) for key variables such as serum PSA levels, Gleason score and clinical stage at time of 
PCa diagnosis; serum PSA levels, T-stage by DRE and biopsy characteristics during follow-up; 
reasons to discontinue AS, treatment choices and cause of death. The database thus has a 
significant amount of highly informative patient data on AS for low risk PCa. It can therefore 
make significant contributions to the development of evidence-based consensus guidelines for 
AS, and as a result, improve the lives of men diagnosed with low risk PCa.  
There are some limitations that need to be considered when using data from GAP3. The 
database is ‘ambidirectional’, meaning that it has both a retrospective and a prospective 
component. Up till now, the GAP3 database is purely a retrospective database. As a 
consequence, there was limited control over data collection, and the data of interest were 
sometimes incomplete or inconsistently measured. For instance, in many cohorts (n=18) the 
reason for discontinuation of AS is not available. For future analyses, the individual centers will 
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be requested to supply the missing data (if available). During the course of the GAP3 project, it 
has become apparent that there is an urgent need to assess the value of MRI with respect to 
disease monitoring in men on AS. The current patient series only has limited imaging data from 
MRI. Currently, almost no data is available for quality of life and genomic testing. However, 
additional funding has now been secured from the Movember Foundation to sustain the database 
and to add a prospective element, thereby providing the opportunity to collect evidence on 
imaging (MRI), molecular (genomics) markers, patient-related outcomes and more.  
Metastatic disease or death from PCa are ultimate end points by which AS should be 
evaluated[16]. However, because of the slow growing nature of low-risk PCa, prospective 
evaluation of these endpoints requires at least another 10–15 years of follow-up[16]. To date, 
mainly data from non-mature prospective clinical trials of AS, that have a mean follow-up of <10 
years, are available. The GAP3 database currently also suffers from limited follow-up time, but 
will in future provide the main resource of real world data on AS management.  
In the global database, PCa death and metastasis remain rare events (both <1%). Current 
analyses therefore make use of surrogate endpoints such as discontinuation of AS and/or changes 
in PCa treatment. Nevertheless, follow-up is ongoing until at least 2019, so that in the future 
GAP3 will contain even more valuable data and provide better insight into patient outcomes.  
 Active surveillance is evolving into a well-accepted management strategy for 
appropriately selected men. Unless the over-diagnosis of indolent PCa is reduced by alternative 
diagnostic strategies, AS will continue to play an important role. The GAP3 initiative will make 
significant contributions to this field of research by offering standard, evidence-based guidelines 
[3]. Clinicians will be able to use these guidelines to more confidently identify men that are 
suitable for active surveillance and to also decide whose PCa has progressed and will, therefore, 
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require treatment.  Such guidelines will provide reassurance to men that they have made the best 
treatment choice for their type of disease [3]. Longer follow-up, achieved by ongoing 
commitment of GAP3 participating centers, and the evaluation of, for instance, imaging and new 
biomarkers, will result in more valuable data and eventually in better patient outcomes. 
Acknowledgements 
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Legends to illustration 
 
Figure 1. Discontinuation of Active Surveillance over time (n=14,033) 
Protocol based progression= clinical and pathological progression, clinical progression, other 
PSA kinetics, pathological progression, PSA progression (PSADT<3 yrs), or radiological 
progression; FU = follow-up; WW = watchful waiting.  
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Table 1 Characteristics at time of PCa diagnosis for all men included in the GAP3 cohort* 
Characteristics Distribution of characteristics  
(N = 15101) 
Number of centers reported (Ntotal=25) 
Age, Median (Q1-Q3) 65 (60-70) 25 
Age, n (%)  25 
≤55 1547 (10.3)  
56-60 2402 (16.1)  
61-65 3579 (23.9)  
66-70 4002 (26.8)  
71-80 3256 (21.8)  
>80 172 (1.1)  
Year of diagnosis, n (%)  25 
1992-1997 260 (1.8)  
1998-2004 1743 (11.6)  
2005-2008 3011 (20.2)  
2009-2011 4101 (27.5)  
2012-2014 4228 (28.4)  
2015-2016 1565 (10.5)  
Charlson Comorbidity Index, n (%)  10 
0 3775 (25.0)  
1 669 (4.4)  
2 761 (5.0)  
≥3 563 (3.7)  
Missing 9333 (61.8)  
T-stage (at DRE), n (%)  23 
T1 10841 (71.8)  
T2 2034 (13.5)  
T3 11 (0.1)  
T4 1 (<0.1)  
Unknown 2214 (14.6)  
Gleason grade group, n (%)  25 
<6 400 (2.7)  
6 13198 (88.8)  
>6 1263 (8.5)  
Unknown 240 (1.6)  
PSA ng/mL. n (%)  25 
0-3.0 1826 (12.6)  
3.1-6.0 6913 (47.8)  
6.1-10.0 4511 (31.2)  
>10.0 1207 (8.3)  
Median (Q1-Q3) 5.4 (4.0-7.3)  
Missing, n (%) 644 (4.3)  
Prostate volume, cc  22 
Median (Q1-Q3) 43.2 (33.0-59.0)  
Missing, n (%) 4069 (26.9)  
PSA density ng/mL/mL  22 
Median (Q1-Q3) 0.12 (0.09-0.17)  
Proportion missing, n (%) 4221 (28.0)  
Positive cores   24 
Median (Q1-Q3) 1 (1-2)  
Missing, n (%) 1305 (8.6%)  
Positive cores  24 
0 78 (0.6)  
1 8321 (60.3)  
2 3270 (23.7)  
≥3 2127 (15.4)  
Percentage of cancer in any one core  17 
      Median (Q1-Q3) 10 (5-20)  
Minimum, maximum 0, 100%  
Proportion missing, n (%) 6114 (40.5)  
*Database version ‘gap3data_2.3’, released in June 2017
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Table 2 Characteristics of clinical follow-up, discontinuation of AS and subsequent treatment* 
 Patient age group at PCa diagnosis  
 50-55 years 
(n=1547) 
56-60 years 
(n=2402) 
61-65 years 
(n=3579) 
66-70 years 
(n=4002) 
71-75 years 
(n=2412) 
>75 years 
(n=1016) 
All** 
N=15101 
Median number of years on AS  
(Q1-Q3) 
2.38  
(1.04-4.63) 
2.21  
(1.07-4.51) 
2.17 
(1.05-4.58) 
2.23 
(1.03-4.50) 
2.12 
(1.04-4.45) 
1.91  
(0.85-3.84) 
2.16 
(1.02-4.47) 
Median number of years until last follow-up 
while on AS (Q1-Q3) 
2.63  
(1.00-5.04) 
2.51 
(1.02-5.07) 
2.50 
(1.02-5.22) 
2.55 
(1.02-5.19) 
2.29 
(1.02-4.85) 
2.04 
(0.87-4.32) 
2.44  
(1.01-5.02) 
Remaining on AS, n (%) 1083 (70.0) 1584 (66.0) 2236 (62.5) 2379 (59.5) 1460 (60.5) 607 (59.7) 9476 (62.8) 
Metastasis, n (%) 4 (0.3) 4 (0.2) 9 (0.3) 11 (0.3) 13 (0.5) 4 (0.4) 45 (0.3) 
Death, n (%)        
Alive 1535 (99.2) 2371 (98.7) 3481 (97.3) 3808 (95.2) 2273 (94.2) 927 (91.2) 14535 (96.2) 
Death due to other causes 11 (0.7) 28 (1.2) 94 (2.6) 180 (4.5) 129 (5.3) 84 (8.3) 529 (3.5) 
Death due to PCa 1 (0.1) 3 (0.1) 4 (0.1) 14 (0.3) 10 (0.4) 5 (0.5) 37 (0.2) 
Discontinuing AS due to different reasons, n (%)      N=5625 (37%) 
Progression 225 (14.5) 435 (18.1) 698 (19.5) 746 (18.6) 386 (16.0) 107 (10.5) 2599 (46.2%) 
Pathological progression 150 (9.7) 276 (11.5) 383 (10.7) 401 (10.0) 190 (7.9) 52 (5.1) 1452 (25.8) 
Other progression 75 (4.8) 159 (6.6) 315 (8.8) 345 (8.6) 196 (8.1) 55 (5.4) 1147 (20.4%) 
Converting to WW 4 (0.3) 10 (0.4) 22 (0.6) 38 (0.9) 63 (2.6) 42 (4.1) 180 (3.3) 
Death 10 (0.7) 18 (0.8) 67 (1.9) 131 (3.3) 95 (3.9) 69 (6.8) 391 (7.0) 
Patients anxiety 53 (3.4) 77 (3.2) 139 (3.9) 138 (3.5) 73 (3.0) 25 (2.5) 511 (9.1) 
Lost-to-follow up 46 (3.0) 72 (3.0) 106 (3.0) 151 (3.8) 105 (4.3) 50 (4.9) 531 (9.4) 
Unknown 128 (8.1) 206 (8.6) 311 (8.7) 419 (10.5) 230 (9.5) 116 (11.4) 1413 (25.1) 
Treatment received following AS, n (%)      N=4124 (73%)*** 
ADT or hormonal therapy  4 (0.3) 18 (0.8) 44 (1.2) 102 (2.5) 105 (4.3) 71 (7.0) 348 (8.4) 
Brachytherapy  34 (2.2) 61 (2.5) 105 (2.9) 113 (2.8) 62 (2.6) 10 (1.0) 385 (9.3) 
Brachytherapy and ADT  1 (0.1) 2 (0.1) 3 (0.1) 5 (0.1) 1 (0.04) 1 (0.1) 13 (0.3) 
EBRT and ADT  2 (0.1) 7 (0.3) 27 (0.8) 62 (1.6) 57 (2.4) 27 (2.7) 182 (4.4) 
EBRT and Brachytherapy  7 (0.5) 28 (1.2) 51 (1.4) 107 (2.7) 46 (1.9) 12 (1.2) 251 (6.1) 
EBRT and Brachytherapy and ADT  2 (0.1) 1 (0.04) 8 (0.2) 8 (0.2) 1 (0.04) 0 (0) 20 (0.5) 
EBRT alone  17 (1.1) 46 (1.9) 115 (3.2) 148 (3.7) 157 (6.5) 62 (6.1) 545 (13.2) 
Focal therapy  4 (0.3) 8 (0.3) 11 (0.3) 13 (0.3) 8 (0.3) 5 (0.5) 54 (1.3) 
Radical prostatectomy  293 (18.9) 462 (19.2) 658 (18.4) 555 (13.9) 145 (6.0) 11 (1.1) 2127 (51.6) 
Radical prostatectomy and ADT 0 (0) 0 (0) 3 (0.1) 4 (0.1) 0 (0) 0 (0) 7 (0.2) 
Radical prostatectomy, ADT and EBRT 0 (0) 0 (0) 1 (0.03) 0 (0) 0 (0) 0 (0) 1 (0.02) 
Radical prostatectomy and EBRT 0 (0) 1 (0.04) 2 (0.1) 0 (0) 1 (0.04) 0 (0) 4 (0.1) 
WW 1 (0.1) 7 (0.3) 12 (0.3) 20 (0.6) 31 (1.3) 13 (1.3) 86 (2.1) 
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 Other 16 (1.0) 18 (0.8) 19 (0.5) 23 (0.6) 15 (0.6) 9 (0.9) 101 (2.5) 
*Database version ‘gap3data_2.3’, released in June 2017; ** The percentage in the last column (All) is based on the total number of patients, the number of patients who 
discontinued AS, or the number of patients who received treatment following AS, respectively; AS: active surveillance;  WW: watchful waiting; EBRT: External beam 
radiotherapy; ADT: Androgen deprivation therapy; PCa: prostate cancer; *** The proportion refers to the % of men that received treatment after stopping AS 
  
 
 
16 
 
Table 3 Clinical and demographic characteristics and clinical follow-up for all men that developed metastases during AS 
and for all men that developed metastases and died of PCa* 
Characteristics Distribution of characteristics of 
men that developed metastases (N 
= 45) 
Distribution of characteristics of men 
that developed metastases and died of 
PCa (N = 17) 
Age, Median (Q1-Q3) 66 yr (IQR 62-72) 66 yr (IQR 64-72) 
Charlson Comorbidity Index, n (%)   
0 45 (100%) 17 (100%) 
1 0 (0%) 0 (0%) 
2 0 (0%) 0 (0%) 
≥3 0 (0%) 0 (0%) 
Missing 0 (0%) 0 (0%) 
T-stage (at DRE), n (%)   
T1 21 (46.7%) 6 (35.3%) 
T2 15 (33.3%) 7 (41.2%) 
T3 2 (4.4%) 1 (5.9%) 
T4 1 (2.2%) 1 (5.9%) 
Unknown 6 (13.3%) 2 (11.8%) 
Gleason grade group, n (%)    
<6 3 (6.7%) 0 (0%) 
6 28 (62.2%) 10 (58.8%) 
>6 21 (46.7%) 5 (29.4%) 
Unknown 4 (8.9%) 2 (11.8%) 
PSA ng/mL. n (%)   
Median (Q1-Q3) 6.9 ng/ml (IQR 4.8-8.7) 7.9 ng/ml (IQR 4.3-12.5) 
Missing, n (%) 4 (8.9%) 1 (5.9%) 
Prostate volume, cc   
Median (Q1-Q3) 44 cc (IQR 31-55) 41 cc (IQR 29-50) 
Missing, n (%) 23 (51.1%) 9 (52.9%) 
PSA density ng/mL/mL   
Median (Q1-Q3) 0.14 ng/ml (IQR 0.10-0.19) 0.14 ng/ml (IQR 0.11-0.19) 
Proportion missing, n (%) 25 (55.6%) 10 (58.8%) 
Positive cores   
0 - - 
1 14 (42.4%) 5 (29.4%) 
2 10 (30.3%) 4 (23.5%) 
≥3 9 (27.3%) 3 (17.6%) 
Time to metastasis, Median (Q1-Q3) 6.4 yr (IQR 3.5-9.9) - 
Time to death, Median (Q1-Q3) - 10.0 (IQR 6.1-12.7) 
*Database version ‘gap3data_2.3’, released in June 2017 
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